Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNA-miR-92a
- Development stage
- Preclinical
- Lead developer
- Universitätsklinikum Münster
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intravenous
01
Overview
LNA-miR-92a (also known as MRG-110 or S95010) is a locked nucleic acid (LNA)-modified antisense oligonucleotide designed to inhibit microRNA-92a (specifically miR-92a-3p). MicroRNA-92a is a key regulator of endothelial cell function, angiogenesis, and tissue repair, and its upregulation is associated with impaired vascularization, inflammation, and fibrosis. By sequestering mature miR-92a, LNA-miR-92a derepresses its target genes (such as ITGA5, SIRT1, KLF2, and KLF4), thereby promoting angiogenesis, reducing inflammation, and mitigating fibrotic remodeling. It has been investigated for the treatment of ischemic heart disease, heart failure, wound healing, and metabolic dysfunction-associated steatohepatitis (MASH/MASLD) with portal hypertension.
- Other names
- LNA-92aLNA92aLNA 92aLNA-antimiR-92aLNA-antimiR92aLNA-antimiR 92aLNA-miR-92a-3pLNA-miR92a-3pLNA-miR 92a-3pmiR-92a inhibitormiR92a inhibitormiR 92a inhibitormicroRNA-92a inhibitormicroRNA92a inhibitormicroRNA 92a inhibitor
02
Targets
miR-92a-3p (MicroRNA-92a-3p)
Beyond the preview
Go deeper on LNA-miR-92a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNA-miR-92a.